MX338554B - Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. - Google Patents

Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.

Info

Publication number
MX338554B
MX338554B MX2014008021A MX2014008021A MX338554B MX 338554 B MX338554 B MX 338554B MX 2014008021 A MX2014008021 A MX 2014008021A MX 2014008021 A MX2014008021 A MX 2014008021A MX 338554 B MX338554 B MX 338554B
Authority
MX
Mexico
Prior art keywords
phenyl carbamate
pain
alleviating
treating
carbamate compounds
Prior art date
Application number
MX2014008021A
Other languages
English (en)
Other versions
MX2014008021A (es
Inventor
Yong Moon Choi
Original Assignee
Bio Pharm Solutions Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Pharm Solutions Co Ltd filed Critical Bio Pharm Solutions Co Ltd
Publication of MX2014008021A publication Critical patent/MX2014008021A/es
Publication of MX338554B publication Critical patent/MX338554B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/26—Polyhydroxylic alcohols containing only six-membered aromatic rings as cyclic part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/36—Polyhydroxylic alcohols containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Un compuesto de fenil carbamato; una composición para tratar y/o aliviar el dolor que contiene el compuesto de fenil carbamato o una sal farmacéuticamente aceptable del mismo como un ingrediente activo; un método de tratamiento y/o alivio el dolor que comprende administrar el compuesto de fenil carbamato o una sal farmacéuticamente aceptable del mismo para un paciente en necesidad del tratamiento del dolor; y un usó del compuesto de fenil carbamato o una sal farmacéuticamente aceptable del mismo en el tratamiento y/o alivio del dolor, se proporcionan.
MX2014008021A 2011-12-27 2012-12-26 Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. MX338554B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161580409P 2011-12-27 2011-12-27
PCT/KR2012/011470 WO2013100567A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain

Publications (2)

Publication Number Publication Date
MX2014008021A MX2014008021A (es) 2014-08-01
MX338554B true MX338554B (es) 2016-04-20

Family

ID=48655156

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014008020A MX353024B (es) 2011-12-27 2012-12-26 Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
MX2014008021A MX338554B (es) 2011-12-27 2012-12-26 Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014008020A MX353024B (es) 2011-12-27 2012-12-26 Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.

Country Status (13)

Country Link
US (6) US20130203846A1 (es)
EP (6) EP2797879B1 (es)
JP (8) JP2015504055A (es)
KR (6) KR101862203B1 (es)
CN (6) CN104870421A (es)
AU (2) AU2012360362B2 (es)
BR (2) BR112014015482A8 (es)
CA (2) CA2858977C (es)
ES (3) ES2624989T3 (es)
IN (2) IN2014MN01432A (es)
MX (2) MX353024B (es)
RU (2) RU2014124029A (es)
WO (6) WO2013100571A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3330104B2 (ja) 1999-07-29 2002-09-30 京セラ株式会社 多数個取りセラミック配線基板の製造方法
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CN104870421A (zh) * 2011-12-27 2015-08-26 比皮艾思药物研发有限公司 用于预防或治疗als的苯基氨基甲酸酯化合物
EP2968210B1 (en) * 2013-03-12 2024-09-11 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
CN105164103B (zh) 2013-03-12 2019-12-06 比皮艾思药物研发有限公司 苯基氨基甲酸酯化合物和含有其的预防或治疗记忆缺失相关疾病的组合物
ES2706184T3 (es) * 2013-12-12 2019-03-27 Bio Pharm Solutions Co Ltd Compuesto derivado de sulfamato para su uso en la prevención o el tratamiento de la epilepsia
US9834535B2 (en) * 2013-12-12 2017-12-05 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating pain
US10351519B2 (en) * 2016-02-29 2019-07-16 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
KR102005019B1 (ko) 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
WO2020010035A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Cannula system
JP7565218B2 (ja) 2018-07-02 2024-10-10 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症および脊髄に関連する障害の治療
KR102427769B1 (ko) 2020-08-07 2022-08-02 한국과학기술연구원 다발성 경화증 예방 또는 치료용 조성물
CA3191072A1 (en) * 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
KR102531540B1 (ko) 2020-09-18 2023-05-16 한국과학기술연구원 류마티스 관절염 예방 또는 치료용 조성물
KR102614653B1 (ko) 2021-06-09 2023-12-20 한국과학기술연구원 신규한 헤테로사이클릴-페닐-메틸아민 유도체, 이의 제조방법 및 이의 다발성 경화증 예방, 개선, 또는 치료 용도
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
WO2023014160A1 (ko) * 2021-08-05 2023-02-09 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법
KR102399807B1 (ko) * 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884444A (en) 1956-01-13 1959-04-28 Carter Prod Inc 2-phenyl-1,3 propane diol dicarbamate
US2937119A (en) 1959-06-11 1960-05-17 Carter Prod Inc Nu-monosubstituted-2, 2-dialkyl-1, 3-propanediol dicarbamates
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3313699A (en) * 1962-06-26 1967-04-11 Armour Pharma Compositions for and method of treating the central nervous system
US3313696A (en) 1962-06-26 1967-04-11 Armour Pharmacentical Company Carbamate sedative compositions and method of use
US3265727A (en) 1962-06-26 1966-08-09 Armour Pharma Phenyl alkyl-1, 2 dicarbamates
US3265728A (en) 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US3313700A (en) * 1962-07-18 1967-04-11 Armour Pharmacentical Company Method of treating the central nervous system with substituted phenethyl carbamates and compositions therefor
FR5671M (es) * 1965-04-23 1968-01-02
US3600427A (en) 1967-05-08 1971-08-17 Anthony J Verbiscar Phenyl carbamate latentiated phenethylamines
JPS61271992A (ja) * 1985-05-28 1986-12-02 Central Glass Co Ltd 光学活性ジオ−ルの製造方法
AU6765394A (en) * 1993-05-25 1994-12-20 Avondale Chemical Company Process for preparing felbamate and intermediates thereto
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
WO2001040168A1 (en) * 1999-11-29 2001-06-07 Mitsubishi Rayon Co., Ltd. Acetalsulfonate derivative, process for producing the same, and process for producing styrene oxide derivative
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CA2439295C (en) * 2001-02-27 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neurodegenerative disorders
BR0207673A (pt) 2001-02-27 2004-12-28 Ortho Mcneil Pharm Inc Compostos de carbamato para o uso no tratamento de dor
WO2002080902A1 (en) 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
KR100912521B1 (ko) 2001-06-25 2009-08-18 에스케이 주식회사 2-헤테로시클릭-1,2-에탄디올의 카바메이트
RU2303445C2 (ru) 2001-07-16 2007-07-27 Орто-Макнейл Фармасьютикал, Инк. Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
NZ533592A (en) * 2001-12-21 2006-05-26 Ortho Mcneil Pharm Inc Process for preparing 2-(substituted phenyl) - 2 - hydroxy-ethyl carbamates
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
WO2003101917A2 (en) 2002-05-31 2003-12-11 Sun Pharmaceutical Industries Limited A process for the preparation of phenylcarbamates
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
AU2004287495A1 (en) 2003-11-05 2005-05-19 Unimed Pharmaceuticals, Inc. Delta-9- the treatment of multiple sclerosis
US7709492B2 (en) * 2004-04-21 2010-05-04 Schering Corporation Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
AU2005254945C1 (en) * 2004-06-08 2013-07-11 Families Of Spinal Muscular Atrophy 2,4-Diaminoquinazolines for spinal muscular atrophy
DE602005020667D1 (de) * 2004-09-16 2010-05-27 Janssen Pharmaceutica Nv Verwendung von 2-phenyl-1,2-ethanediol-(di)carbamaten zur behandlung von epileptogenese
CN101076327A (zh) * 2004-10-15 2007-11-21 詹森药业有限公司 用于治疗神经变性疾病的氨基甲酸酯化合物
US7442438B2 (en) 2005-05-04 2008-10-28 3M Innovative Properties Company Wet and dry stick adhesive, articles, and methods
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
ZA200900161B (en) * 2006-07-28 2010-05-26 Eisai R&D Man Co Ltd Prodrug of cinnamide compound
AR062095A1 (es) * 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
AU2007307029A1 (en) * 2006-10-06 2008-04-17 Transform Pharmaceuticals, Inc. Novel crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
EP2089002A1 (en) * 2006-10-13 2009-08-19 Janssen Pharmaceutica, N.V. Phenylalkyl carbamate compositions
KR20090085071A (ko) 2006-10-27 2009-08-06 얀센 파마슈티카 엔.브이. 달팽이관 및 전정기관 장애의 치료 방법
EA200970436A1 (ru) 2006-10-30 2009-12-30 Янссен Фармацевтика, Н.В. Соединения карбамата для лечения депрессии
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
US8242280B2 (en) 2007-04-10 2012-08-14 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
WO2009022345A1 (en) 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
US20090105498A1 (en) * 2007-10-18 2009-04-23 Porstmann Frank Improved process for preparing 2-(substituted phenyol)-2-hydroxy-ethyl-carbamates
CA2734651A1 (en) 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating neuropathic pain
JP2011219387A (ja) * 2010-04-06 2011-11-04 Kaneka Corp イオン液体の製造方法
JP5774694B2 (ja) * 2010-07-02 2015-09-09 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート化合物およびこれを含む筋肉弛緩剤
US9018253B2 (en) * 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
KR101551041B1 (ko) 2011-01-13 2015-09-07 (주)바이오팜솔루션즈 페닐 카바메이트 유도체의 제조방법
CA2828478C (en) * 2011-02-28 2019-12-31 Array Biopharma Inc. Serine/threonine kinase inhibitors
CN104870421A (zh) * 2011-12-27 2015-08-26 比皮艾思药物研发有限公司 用于预防或治疗als的苯基氨基甲酸酯化合物

Also Published As

Publication number Publication date
KR20140113914A (ko) 2014-09-25
EP2797878A1 (en) 2014-11-05
EP2797879A1 (en) 2014-11-05
US20130165509A1 (en) 2013-06-27
CN104136413B (zh) 2016-10-26
JP2015506934A (ja) 2015-03-05
JP2015504054A (ja) 2015-02-05
JP6155280B2 (ja) 2017-06-28
CN104136416A (zh) 2014-11-05
JP6298765B2 (ja) 2018-03-20
EP2797881A4 (en) 2016-01-13
CA2859129A1 (en) 2013-07-04
BR112014015482A8 (pt) 2017-07-04
EP2797881B1 (en) 2018-11-14
KR101880584B1 (ko) 2018-07-20
JP2018108996A (ja) 2018-07-12
EP2797877A1 (en) 2014-11-05
CA2858977C (en) 2020-06-23
KR20140113918A (ko) 2014-09-25
RU2632659C2 (ru) 2017-10-09
CN104169253B (zh) 2016-11-09
EP2797880B1 (en) 2017-03-01
KR101795562B1 (ko) 2017-11-08
CN104136415B (zh) 2016-09-07
EP2797879A4 (en) 2015-10-07
IN2014MN01436A (es) 2015-07-03
EP2797876A4 (en) 2015-10-07
EP2797878A4 (en) 2015-10-07
EP2797881A1 (en) 2014-11-05
MX353024B (es) 2017-12-18
AU2012360362A1 (en) 2014-08-07
CN104169253A (zh) 2014-11-26
US9029589B2 (en) 2015-05-12
AU2012360365B2 (en) 2017-08-31
BR112014015482A2 (pt) 2017-06-13
BR112014015568A8 (pt) 2017-07-04
US20130165410A1 (en) 2013-06-27
WO2013100567A8 (en) 2014-02-20
AU2012360365A1 (en) 2014-08-07
US20130165409A1 (en) 2013-06-27
BR112014015568A2 (pt) 2017-06-13
US9162975B2 (en) 2015-10-20
RU2014124028A (ru) 2016-02-20
KR20140108245A (ko) 2014-09-05
CN104136416B (zh) 2016-11-09
MX2014008021A (es) 2014-08-01
RU2014124029A (ru) 2016-02-20
CN104136413A (zh) 2014-11-05
KR101795563B1 (ko) 2017-11-08
WO2013100571A1 (en) 2013-07-04
US9034848B2 (en) 2015-05-19
EP2797880A4 (en) 2015-10-07
WO2013100567A1 (en) 2013-07-04
AU2012360362B2 (en) 2017-08-31
ES2716832T3 (es) 2019-06-17
BR112014015568B1 (pt) 2022-03-29
JP2015504053A (ja) 2015-02-05
EP2797876A1 (en) 2014-11-05
CN104136414A (zh) 2014-11-05
WO2013100568A1 (en) 2013-07-04
MX2014008020A (es) 2014-12-08
ES2624989T3 (es) 2017-07-18
EP2797880A1 (en) 2014-11-05
EP2797878B1 (en) 2017-08-16
CN104870421A (zh) 2015-08-26
KR20140113919A (ko) 2014-09-25
IN2014MN01432A (es) 2015-07-03
KR101862203B1 (ko) 2018-05-29
WO2013100570A1 (en) 2013-07-04
JP6298766B2 (ja) 2018-03-20
WO2013100571A9 (en) 2014-09-18
JP2015504055A (ja) 2015-02-05
CA2858977A1 (en) 2013-07-04
KR20140108226A (ko) 2014-09-05
EP2797877A4 (en) 2015-10-07
ES2710902T3 (es) 2019-04-29
CA2859129C (en) 2020-07-14
JP2017193577A (ja) 2017-10-26
JP2015503550A (ja) 2015-02-02
US20130165408A1 (en) 2013-06-27
WO2013100569A1 (en) 2013-07-04
KR20150023217A (ko) 2015-03-05
JP6089045B2 (ja) 2017-03-01
WO2013100566A8 (en) 2014-02-20
WO2013100566A1 (en) 2013-07-04
EP2797879B1 (en) 2018-12-26
US9624164B2 (en) 2017-04-18
JP2015508398A (ja) 2015-03-19
CN104136415A (zh) 2014-11-05
US20130184338A1 (en) 2013-07-18
US20130203846A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
MX2014008021A (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
PH12014500386A1 (en) Combination treatment for hepatitis c
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
MX2013012588A (es) Inhibidores de cinasa.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
PH12016502355A1 (en) Pharmaceutical composition
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
MX360030B (es) Metodos para tratar el trastorno bipolar.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2013003638A (es) Tratamiento en combinacion para rosacea.
EP2490700A4 (en) EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
PH12013500371A1 (en) Therapeutic agent for pain
IN2014KN01113A (es)
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
TW201129361A (en) Methods for treating pain
SI3882244T1 (sl) Spojina, farmacevtsko sprejemljiva sol ali optični izomer le-te, postopek za njeno pripravo in farmacevtski sestavek za preprečevanje ali zdravljenje virusnih bolezni, ki jo vsebuje kot učinkovino
MX358189B (es) Derivados de pirimidina para el tratamiento de enfermedades bacterianas.
WO2011156900A3 (en) Compounds, compositions and methods for treatment of multiple sclerosis
PH12013501638A1 (en) (5s,8s)-3-(4`-chlor-3`-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment
HK1194739A (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders

Legal Events

Date Code Title Description
FG Grant or registration